Clinical trial · Interventional
Vaccine Therapy in Treating Patients With Metastatic Cancer
Immunization of HLA-A*0201 Patients With Metastatic Cancer Using a Peptide Epitope From the Telomerase Antigen
NCT00021164CI-TRIAL-00010782completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aldesleukin | Biological | Aldesleukin | ALIAS |
| incomplete Freund's adjuvant | Biological | — | UNRESOLVED |
| telomerase: 540-548 peptide vaccine | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Presenting with evaluable metastatic cancer * Refractory to standard treatment OR * Post-radiation for malignant glioma * HLA-A\*0201 expression PATIENT CHARACTERISTICS: Age: * 16 and over Performance status: * ECOG 0-2 Life expectancy: * More than 3 months Hematopoietic: * WBC at least 3,000/mm\^3 * Platelet count at least 90,000/mm\^3 Hepatic: * Bilirubin no greater than 1.6 mg/dL * AST/ALT less than 3 times normal * Hepatitis B surface antigen negative Renal: * Creatinine no greater than 2.0 mg/dL Cardiovascular: * No cardiac ischemia by stress thallium or comparable test\* * No prior myocardial infarction\* * No cardiac arrhythmias\* NOTE: \*Patients receiving interleukin-2 (IL-2) only Pulmonary: * No obstructive or restrictive pulmonary disease (patients receiving IL-2 only) Immunologic: * HIV negative * No autoimmune disease or any other known immunodeficiency disease * No active primary or secondary immunodeficiency Other: * No other active major medical illness\* * No active systemic infection * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception NOTE: \*Patients receiving IL-2 only PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior telomerase: 540-548 peptide immunization Chemotherapy: * Recovered from prior chemotherapy Endocrine therapy: * No requirement for systemic steroid therapy Radiotherapy: * See Disease Characteristics * Recovered from prior radiotherapy Surgery: * Not specified Other: * At least 3 weeks since prior systemic therapy for cancer
References
Publications (0)
Data not yet available
No reference posted for this study.